![Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease]()
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart diseaseVon Bibra, Helene; Diamant, Michaela; Scheffer, Peter G; Siegmund, Thorsten; Schumm-Draeger, Petra-Maria · Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease · 2008